Malcolm K Brenner

This inventor holds 14 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Baylor College of Medicine, Advisys, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2007-2026.

USPTO Granted Patents = 14 (Patent Applications = 14)

% Patents Active = 92.9

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 10)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 75(Granted Patents)

Location History:

Houston, TX (US) (2016 - 2022)
Bellaire, TX (US) (2007 - 2024)

Company Filing History:

13 out of 614

Baylor College of Medicine

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4. 1 out of 18

Vgx Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617838 - AUTO/ALLO-IMMUNE DEFENSE RECEPTORS FOR THE SELECTIVE TARGETING OF ACTIVATED PATHOGENIC T CELLS AND NK CELLS (2026-05-05),

2. 12377147 - Reprogramming CD4 t cells into cytotoxic CD8 cells by forced expression of CD8ab and class 1 restricted t cell receptors (2025-08-05),

3. 11896634 - Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules (2024-02-13),

4. 11547740 - Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy (2023-01-10),

5. 11266726 - Compositions and methods for the treatment of HER2-expressing solid tumors (2022-03-08),

6. 11077176 - Methods for inducing selective apoptosis (2021-08-03),

7. 10786549 - CD5 chimeric antigen receptor for adoptive T cell therapy (2020-09-29),

8. 10716818 - Oncolytic virotherapy and immunotherapy (2020-07-21),

9. 10279009 - Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy (2019-05-07),

10. 9493740 - Immunotherapy of cancer using genetically engineered GD2-specific T cells (2016-11-15),

11. 9393292 - Methods for inducing selective apoptosis (2016-07-19),

12. 9089520 - Methods for inducing selective apoptosis (2015-07-28),

13. 8178504 - Gene therapy expression of GHRH for increasing RBC count in subjects (2012-05-15),

14. 7241744 - Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone (2007-07-10),

Title: The Innovative Journey of Malcolm K Brenner

Introduction: Malcolm K Brenner, a distinguished inventor hailing from Bellaire, TX (US), has made significant contributions to the field of innovations with his groundbreaking ideas and inventions.

Latest Patents: Malcolm K Brenner holds several patents in various technological domains, showcasing his versatility and creativity in inventing novel solutions to complex problems.

Career Highlights: Throughout his illustrious career, Malcolm K Brenner has demonstrated a keen eye for identifying gaps in the market and developing innovative products to fill those voids. His dedication to pushing the boundaries of what is possible has earned him a reputation as a visionary inventor.

Collaborations: Malcolm K Brenner has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many of his projects.

Conclusion: In conclusion, Malcolm K Brenner's passion for innovation, coupled with his relentless drive to create, has solidified his position as a prominent figure in the world of inventors. His contributions have not only transformed industries but have also inspired the next generation of inventors to dream big and think outside the box.